ARETE BIOSCIENCES

Medtech · Private

Point-of-care molecular test for active Hepatitis C Virus (HCV) detection using nucleic acid amplification

Grants
$307K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
$995K
2 awards · Health and Human S
#321 of 4531 in medtech
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal contractDepartment of Health and Human Services · Rapid Acceleration Of Diagnostics (radx) Program Tech$250,000
Federal contractDepartment of Health and Human Services · Dev Of An Ultra-sensitive And Cost-effective Home-based Disposable Molecular Platform For SARS-COV-2 Testing Arete Biosciences Aoi #4.1 COVID-19$745,000
Federal grantDepartment of Health and Human Services · Phase I · Development of an ultrasensitive, rapid and portable nucleic acid based test for detection of acute Hepatitis C Virus infection at the point-of-care.$306,992
Federal grant · SBIR/STTRFederal contract · USAspending

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
318BIOWAVE CORP$1.0M$1.7M
319ZETROZ SYSTEMS LLC$1000K—
320Caregility Corp$997K$7.5M
321ARETE BIOSCIENCES$995K—
322CROSSLIFE TECHNOLOGIES INC.$966K—
323SHOULDER INNOVATIONS, INC.$966K$81M
324Securisyn Medical, LLC$958K$11M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Timed System for Rapid Assayapplication
  • Methods for Analyzing Nucleic Acidsapplication
  • Methods and Reagents for Analyzing Nucleic Acidsapplication

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.